Amgen

Amgen completes Onyx merger

Wednesday, October 2, 2013 01:01 PM

Amgen has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals for $125 per share in cash. As announced Aug. 25, the purchase price is $9.7 billion net of estimated Onyx cash.

More... »

Amgen, ShanghaiTech University plans for Amgen China R&D center

Wednesday, September 25, 2013 03:12 PM

Amgen and ShanghaiTech University have partnered for the advancement of biopharmaceutical discovery and translational research in China, with plans for Amgen to open a China R&D center at ShanghaiTech University.

More... »

Analysis highlights predictive biomarkers discovery for Vectibix

Monday, September 16, 2013 03:11 PM

Amgen has published a biomarker analysis of Vectibix (panitumumab) in combination with FOLFOX, a type of oxaliplatin-based chemotherapy, for the first-line treatment of patients with metastatic colorectal cancer (mCRC). Published in the New England Journal of Medicine, the analysis found that RAS mutations, beyond the known KRAS exon 2 mutations, predict lack of response to Vectibix in combination with FOLFOX. RAS mutations are mutations occurring in exons 2, 3 and 4 of KRAS and NRAS.

More... »

Amgen to acquire Onyx Pharmaceuticals

Monday, August 26, 2013 12:07 PM

Amgen will acquire San Francisco, Calif.-based Onyx Pharmaceuticals, purchasing all of the outstanding shares of Onyx for $125 per share in cash, for a total purchase price of $10.4 billion, or $9.7 billion net of estimated Onyx cash. The boards of both companies have approved the transaction.

More... »

Amgen, Servier complete product collaboration

Thursday, August 15, 2013 09:30 AM

Biotechnology company Amgen and privately-run French research-based pharmaceutical company Servier have announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement announced  July 8, completing the transaction.

More... »

Teijin Pharma, Amgen collaborate for autoimmune diseases

Monday, August 5, 2013 11:57 AM

Teijin Pharma has entered into a collaborative agreement with Amgen to discover, develop and commercialize small molecule drugs that target RORγ. The agreement grants Amgen an option to obtain a worldwide (excluding Japan) exclusive license to compounds discovered in the joint research collaboration, while Teijin Pharma will hold exclusive rights in Japan. Teijin Pharma will also have the right to co-promote potential products in select Asian markets.

More... »

Amgen, Servier announce product collaboration

Thursday, July 11, 2013 01:01 PM

Biotechnology company Amgen and privately-run French research-based pharmaceutical company Servier have entered a collaboration agreement leveraging each company's commitment to cardiovascular disease.

More... »

Loxo Oncology, Array BioPharma in license, collaboration agreement

Thursday, July 11, 2013 09:10 AM

Loxo Oncology, a biopharmaceutical company established and funded by Aisling Capital, and Array BioPharma have announced a multi-year license and collaboration agreement for an Array-invented preclinical development candidate and related intellectual property. In addition, Loxo and Array will collaborate to discover and develop small molecule drugs for mutually agreed upon novel oncology targets. 

More... »

SCRS launches Global Impact Partnership Program

Friday, June 21, 2013 10:35 AM

The Society for Clinical Research Sites (SCRS) has launched the Global Impact Partnership (GIP) Program. In just over one month, 12 organizations have joined as partners to provide ongoing development, feedback and support of industry initiatives designed to include and improve the voice of clinical research sites. 

More... »

Amgen, Cytokinetics expand collaboration

Thursday, June 13, 2013 01:30 PM

Amgen and Cytokinetics, a clinical-stage biopharmaceutical company, have expanded their strategic collaboration to include Japan. In 2006, Cytokinetics and Amgen entered into a collaboration to discover, develop and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure. Omecamtiv mecarbil is the most advanced drug candidate in this collaboration.  

More... »